Key result
High Lp(a) is linked to ~77% higher major cardiovascular events risk only in women off hormone therapy.
Why the study?
Does hormone therapy modify the association between high Lipoprotein(a) levels and cardiovascular events in initially healthy women?
Cohort (n=27,736)
Does hormone therapy modify the association between high Lipoprotein(a) levels and cardiovascular events in initially healthy women?
Answers are grounded in this paper and cite their sources.
Hormone therapy attenuates the predictive utility of high Lipoprotein(a) levels for future cardiovascular events in women.
Objective This study assesses whether the relationship of lipoprotein(a) (Lp(a)) with cardiovascular risk may be modified by concurrent hormone therapy (HT). Background Prior studies indicate that hormone therapy (HT) decreases plasma levels of Lp(a), but few have been powered to assess whether it modifies the relationship of Lp(a) with cardiovascular disease (CVD). Methods Lp(a) at baseline was measured among 27,736 initially healthy women, of whom 12,075 indicated active HT use at the time of blood draw at study initiation, and 15,661 did not. The risk of first-ever major cardiovascular event (nonfatal myocardial infarction, nonfatal cerebrovascular event, coronary revascularization or cardiovascular deaths) over a ten-year period was assessed in Cox-proportional hazard models according to Lp(a) levels and HT status, and adjusted for potential confounding variables. Results As anticipated, Lp(a) values were lower among women taking HT (median 9.4 vs. 11.6 mg/dL, P<0.0001). In women not taking HT, the hazard ratio of future CVD for the highest Lp(a) quintile compared to the lowest was 1.8 (P-trend <0.0001), after adjusting for age, smoking, blood pressure, diabetes, body mass index, total cholesterol, HDL, C-reactive protein and treatment arms of aspirin and Vitamin E. In contrast, among women taking HT, there was little evidence of association with CVD [hazard ratio 1.1, P-trend =0.18; interaction P-value 0.0009 between Lp(a) quintiles and HT on incident CVD]. Conclusion The relationship of high Lp(a) levels with increased CVD is modified by hormone therapy. These data suggest that the predictive utility of Lp(a) is markedly attenuated among women taking HT, and may inform clinicians’ interpretation of Lp(a) values in such patients.
No takes yet. Share an insight, caveat, or question.
Danik et al. (2008) conducted a cohort in Healthy women (primary prevention) (n=27,736). Highest quintile of Lipoprotein(a) vs. Lowest quintile of Lipoprotein(a) was evaluated on First-ever major cardiovascular event (nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization or cardiovascular death) (HR 1.77, 95% CI 1.36-2.30, p=<0.0001). The highest quintile of Lipoprotein(a) was associated with a 77% increased risk of major cardiovascular events in women not taking hormone therapy, but this risk was markedly attenuated in women taking hormone therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: